Advertisement
Advertisement
NBP
NovaBridge Biosciences - ADR
0.86
USDSponsored
-0.05
-5.36%
Nov 10, 15:59 UTC -5
Closed
After-Market
0.86
0.00
-0.01%
NovaBridge Biosciences - ADR (NBP) Earnings
NBP Earnings Reports
Positive Surprise Ratio
NBP beat 4 of 8 last estimates.
50%
Next Report
Date of Next Report
Apr 05, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.08
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/-71.43%
NovaBridge Biosciences - ADR earnings per share and revenue
On Aug 20, 2026, NBP reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.14 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q4 26, 2 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were NovaBridge Biosciences - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, NovaBridge Biosciences - ADR reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to NovaBridge Biosciences - ADR's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is NovaBridge Biosciences - ADR expected to report next?
The next earning report is scheduled for Apr 05, 2027.
What are the forecasts for NovaBridge Biosciences - ADR's next earnings report?
Based on 2
analysts, NovaBridge Biosciences - ADR is expected to report EPS of -$0.08 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.